Immunohistochemical and functional biomarkers of value in female genital tract lesions.
There has been a marked expansion in the literature pertaining to the use of immunohistochemical markers in female genital tract pathology, especially with regard to diagnosis. This review provides a survey of the antibodies commonly used in the diagnosis of gynecological lesions grouped as to function or type. Prognostic or predictive markers are also discussed where appropriate, although few of these are of value in everyday practice. It is stressed that when immunohistochemistry is used diagnostically, panels of markers provide better information than reliance on a single antibody.
McCluggage
W Glenn
WG
Department of Pathology, Royal Group of Hospitals Trust, Belfast, Northern Ireland. glenn.mccluggage@bll.n-i.nhs.uk
D015415:Biomarkers / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002448:Cell Adhesion; D002453:Cell Cycle / Q000502:physiology; D002454:Cell Differentiation; D004848:Epithelium / Q000737:chemistry; D005260:Female; D005831:Genital Diseases, Female / Q000175:diagnosis* / Q000378:metabolism; D005833:Genital Neoplasms, Female / Q000737:chemistry / Q000175:diagnosis*; D006801:Humans; D007150:Immunohistochemistry; D008648:Mesoderm / Q000737:chemistry; D011237:Predictive Value of Tests; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000032:analysis
D015415:Biomarkers; D014408:Biomarkers, Tumor; D011956:Receptors, Cell Surface